Bayer initiates asundexian Phase III study program
© Reuters. FILE PHOTO: The logo of Bayer AG is pictured on the facade of the historical headquarters of the German pharmaceutical and chemical maker in Leverkusen, Germany, April 27, 2020. REUTERS/Wolfgang Rattay/File Photo
BERLIN (Reuters) – Germany’s Bayer (OTC:BAYRY) said on Sunday it was starting a Phase III study program to investigate the efficacy and safety of asundexian, an oral Factor XIa (FXIa) inhibitor.
The drug candidate is a potential new treatment for patients with atrial fibrillation and in patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, Bayer said.
Bayer’s best-selling stroke prevention pill Xarelto, in which partner Johnson & Johnson (NYSE:JNJ) holds some rights, will lose patent protection around 2026.